SCHEMBL21943452

SCHEMBL21943452

Cc1ccc(Oc2cc(-c3ccncc3)nc3c2ccn3C)cc1C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.47
▸ MAPK14 Q16539 5/20 0.47
▸ KIT P10721 4/20 0.47
▸ CSF1R P07333 3/20 0.47
▸ MET P08581 1/20 0.47
▸ LCK P06239 4/20 0.46
▸ SRC P12931 1/20 0.46
▸ POLB P06746 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ BRAF P15056 3/20 0.45
▸ RXFP1 Q9HBX9 4/20 0.45
▸ MAPT P10636 1/20 0.45
▸ FLT1 P17948 2/20 0.44
▸ TEK Q02763 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ FLT4 P35916 1/20 0.44
▸ TNNI3K Q59H18 1/20 0.44
▸ IDE P14735 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943013 0.92 MAPK14 (0.54) KDRMAPK14KITCSF1RMET
SCHEMBL21943069 0.88 KDR (0.51) KDRKITPOLBKDM4EBRAF
SCHEMBL21943451 0.87 KDR (0.58) KDRMAPK14KITCSF1RMET
SCHEMBL21943450 0.87 BRAF (0.51) KDRMAPK14KITPOLBKDM4E
SCHEMBL21943684 0.85 KDR (0.51) KDRMAPK14KITCSF1RMET
SCHEMBL21943657 0.85 BRAF (0.53) KDRMAPK14KITCSF1RMET
SCHEMBL21943519 0.84 CSF1R (0.54) KDRMAPK14KITCSF1RLCK
SCHEMBL22024638 0.81 RXFP1 (0.51) KDRKITCSF1RPOLBKDM4E
SCHEMBL21943070 0.81 MEN1 (0.53) KDRMAPK14KITCSF1RMET
SCHEMBL22065428 0.80 POLB (0.58) KDRMAPK14KITCSF1RMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
EP-3647313-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF Xiamen University (CN) 2020-05-06 — — EP disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 KDR 2067/4885MAPK14 926/4885KIT 603/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 KDR 2067/4885MAPK14 926/4885KIT 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback